0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > FOLR2

FOLR2

FOLR2 Molecule Information

Name:Folate receptor beta
Target Synonym:Placental folate-binding protein;Folate receptor 2;FOLR2;Folate receptor beta;FR-beta;FBP;Folate receptor, fetal/placental
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:6
Lastest Research Phase:Phase ?

FOLR2 Protein Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
FO2-H5223 Human Human FOLR2 Protein, His Tag
FO2-H5223-structure
FO2-H5223-sds
FO2-H5223-elisa_1

FOLR2 Molecule Synonym Name

FOLR2,BETA-HFR,FBP/PL-1,FR-BETA,FR-P3,FBP

FOLR2 Molecule Background

Folate receptor beta is also known as Folate receptor 2, FBP, FOLR2, BETA-HFR, FBP/PL-1, FR-BETA, FR-P3, and is a member of the folate receptor (FOLR) family. and mediate delivery of 5-methyltetrahydrofolate to the interior of cells. This protein has a 68% and 79% sequence homology with the FOLR1 and FOLR3 proteins, respectively. The FOLR2 protein was originally thought to exist only in placenta, but is also detected in spleen, bone marrow, and thymus. FOLR2 is predominantly expressed in placenta, cells of the neutrophilic lineage, and some CD34+ hematopoietic progenitor cells. It is upregulated on myeloid leukemias, head and neck squamous cell carcinomas, and several nonepithelial cancers. It is also upregulated on macrophages and monocytes at chronic inflammatory sites including rheumatoid arthritis synovium and glioblastoma. FOLR2 is a marker for macrophages generated in the presence of M-CSF, but not GM-CSF. Its expression correlates with increased folate uptake ability. Folate conjugates of therapeutic drugs are a potential immunotherapy tool to target tumor-associated macrophages.

FOLR2 References

FOLR2 Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Vintafolide MK-8109; EC-145 Phase Ⅱ Novartis, Merck Sharp & Dohme Non small cell lung cancer (NSCLC) Details
EC-1456 EC-1456; EC-0531 Phase Ⅰ Novartis Non small cell lung cancer (NSCLC), Ovarian cancer Details
EC-0905 EC-0905 Preclinical Novartis Cancer Details
OTL-38 OTL-38; OTL-0038; Pteroyl-L-Tyr-S0456; EC-17 Phase Ⅲ On Target Ovarian cancer Details
Epofolate BMS-753493 Phase Ⅱ Bristol-Myers Squibb, Novartis Solid tumours Details
EC-0305 EC-0305; F-0305 Phase Ⅰ Novartis Solid tumours Details

This web search service is supported by Google Inc.

totop